Co-delivery of Cu(I) chelator and chemotherapeutics as a new strategy for tumor theranostic

Tao Sun; Guangping Zhang; Zhongyuan Guo; Qinjun Chen; Yujie Zhang; Yongchao Chu; Qin Guo; Chao Li; Wenxi Zhou; Yiwen Zhang; Peixin Liu; Hongyi Chen; Haijun Yu; Liping Jiang; Chen Jiang

doi:10.1016/j.jconrel.2020.02.023

Co-delivery of Cu(I) chelator and chemotherapeutics as a new strategy for tumor theranostic

J Control Release. 2020 May 10:321:483-496. doi: 10.1016/j.jconrel.2020.02.023. Epub 2020 Feb 28.

Authors

Tao Sun¹, Guangping Zhang², Zhongyuan Guo¹, Qinjun Chen¹, Yujie Zhang¹, Yongchao Chu¹, Qin Guo¹, Chao Li¹, Wenxi Zhou¹, Yiwen Zhang¹, Peixin Liu¹, Hongyi Chen¹, Haijun Yu³, Liping Jiang⁴, Chen Jiang⁵

Affiliations

¹ Key Laboratory of Smart Drug Delivery (Ministry of Education), Minhang Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Department of Pharmaceutics, School of Pharmacy, Research Center on Aging and Medicine, Fudan University, Shanghai 201203, PR China.
² Shandong Province Key Laboratory of Medical Physics and Image Processing Technology, School of Physics and Electronics & Institute of Materials and Clean Energy, Shandong Normal University, 1 University Road, Jinan, 250358, PR China.
³ State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China.
⁴ State key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai 200438, PR China.
⁵ Key Laboratory of Smart Drug Delivery (Ministry of Education), Minhang Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Department of Pharmaceutics, School of Pharmacy, Research Center on Aging and Medicine, Fudan University, Shanghai 201203, PR China. Electronic address: [email protected].

PMID: 32061623
DOI: 10.1016/j.jconrel.2020.02.023

Abstract

Chelating Cu from tumors has been verified as an effective and promising strategy for cancer therapy through antiangiogenesis. However, systematic removal Cu by injecting with Cu chelators will result unavoidable side effects, since Cu is indispensable to the body. In this work, a micelle targeting to tumors' newborn vessels based on a polypeptide was developed to co-load DOX and Probe X, which can go through an "OFF-to-ON" procedure to report the Cu⁺-capture events in vivo in a real-time way by giving near infrared (NIR) fluorescence and photoacoustic signal. By co-delivering antiangiogenesis and chemotherapeutic reagents, the tumor can be significantly suppressed, meanwhile with a low systematic toxicity. Hopefully, this work can offer new insights in designing sophisticated antitumor strategy.

Keywords: Antiangiogenesis; Co-delivery; Cu chelator; Real-time reporting; Theranostic.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cell Line, Tumor
Chelating Agents*
Copper
Drug Delivery Systems
Humans
Infant, Newborn
Micelles
Neoplasms* / drug therapy
Precision Medicine*
Theranostic Nanomedicine

Substances

Chelating Agents
Micelles
Copper